Conference Presentation, Panel
Ebola and Economy: The Cost of Infectious Disease
Milken InstituteTom Evans, Michel Deville, Catherine Deland, Gabrielle Fitzgerald, Dr. Pranav Shetty, Nancy Ossie
- Global Funding Scale: Approximately $3.2 billion has been raised for the Ebola response, with outstanding pledges bringing the total to nearly $4 billion in a remarkably short timeframe.
- Economic Devastation: The Ebola outbreak caused an estimated $32 billion loss to the economies of Guinea, Sierra Leone, and Liberia, decimating the tourism and infrastructure sectors.
- Growth Reversal: The crisis halted economic growth in the affected West African nations, which had previously among the highest GDP growth rates globally, forcing them into flat growth for an extended period.
- Historical Mortality Context: In 2014, Tuberculosis caused approximately 1.5 million deaths compared to roughly 2,000 deaths from Ebola, highlighting the disparity in attention between the two epidemics.
- XDR-TB Comparison: Extensively Drug-Resistant Tuberculosis (XDR-TB) carries a mortality rate of 30–70%, similar to Ebola, yet represents a larger, ongoing crisis with twice as many cases as Ebola.
- R&D Investment Disparity: In neglected disease research, HIV/AIDS accounts for roughly one-third of funding, while TB and Malaria each receive one-sixth; Ebola and other hemorrhagic fevers historically receive trivial funding despite high mortality.
- Vaccine Development Acceleration: While traditional vaccine development takes 5–10 years, three advanced Ebola vaccine candidates moved from preclinical to Phase I/II/III trials and potential registration within 18 months of the crisis onset.
- Source of Innovation: The accelerated Ebola vaccine pipeline originated primarily from academia and biotech firms (e.g., Ocario, a Canadian biotech, and GSK via acquisition), rather than traditional large pharmaceutical R&D departments.
- Regulatory Pivot: Regulatory authorities adopted an "animal efficacy" pathway, allowing licensure based on preclinical data without waiting for epidemic resolution, coupled with strict post-marketing surveillance commitments.
- Operational Failure Timeline: The global response was delayed by three months in Guinea (December 2013–March 2014) due to a lack of local detection capabilities, allowing the virus to spread unchecked.
- Critical Control Measures: The epidemic curve was inverted by increasing safe and dignified burial teams, expanding isolation beds, and enforcing strict behavioral changes to prevent family-to-family transmission.
- Current Response Phase: The strategy has shifted from containment to aggressive case finding, contact tracing, and fostering community ownership to eliminate the final "last 5%" of cases and prevent resurgence.
- Healthcare Workforce Crisis: A shortage of approximately 7.2 million global health workers is projected over the next 20 years, a deficit that significantly hampered the initial response capacity in West Africa.
- UN System Reform: For the first time in history, the UN established a dedicated public health mission (UN Mission for Ebola Emergency Response), signaling a departure from traditional peacekeeping-only mandates.
- BRICS Engagement: Emerging economies, specifically China, actively participated in the response with military assets and funding, sitting at the same decision-making tables as G7 nations for the first time in this context.
- Philanthropic Gap: Early philanthropic involvement was limited until Paul Allen's $100 million pledge in late 2014 acted as a catalyst, leading to increased contributions from Silicon Valley figures like Mark Zuckerberg.
- Structural Recommendations: Panelists advocate for a standing "Global Health Emergency Workforce" under WHO leadership, with surge capacity ready for the first 30 days of any future crisis.
- Funding Mechanisms: Proposals include a pandemic emergency fund modeled after the World Bank's concept and innovative financing such as a passenger flight tax to generate sustainable revenue for preparedness.
- Local Health Systems: Experts emphasize that effective global response is impossible without first strengthening local health systems, noting that the differential in preparedness between Vancouver and Toronto during SARS dictated the scale of the outbreak.
- Zoonotic Prevention: The crisis highlighted the need for public-private partnerships addressing upstream drivers like deforestation, wildlife trade, and climate change to prevent future spillover events.
- Future Outlook: While the immediate Ebola outbreak is projected to be controlled within two years, the panel anticipates a higher risk of recurrence in affected communities and urges continued vigilance against other threats like XDR-TB and future pandemics.